Cuscal (CCL) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
24 Feb, 2026Executive summary
Achieved 9% transaction volume growth and 13% underlying NPAT growth for the half year ended December 31, 2025, reflecting strong operational performance and the completed Indue acquisition.
Statutory NPAT rose 76% to $21.5m, with underlying NPAT at $24.2m, supported by both organic and inorganic growth.
Completed the acquisition of Indue Limited on December 1, 2025, for $75.2m, with integration progressing as planned and expected cost synergies on track.
Declared an interim dividend of 4.5 cents per share, fully franked, consistent with the prior year.
Maintained a strong capital position, supporting ongoing investment and dividend payments.
Financial highlights
Net operating income grew 10% year-over-year to $161.5m, including a $5.3m contribution from Indue.
Underlying NPAT increased 13% to $24.2m; EPS up 4% to 12.6 cps, reflecting increased share count post-IPO.
Statutory NPAT rose 76% to $21.5m, with non-recurring acquisition, integration, and IPO costs impacting results.
Operating expenses rose 10% to $127.5m, mainly due to higher employee costs and technology investment.
Adjusted EBITDA increased 8% to $38.5m.
Outlook and guidance
Upgraded outlook: high single-digit transaction volume growth expected to drive mid-teens underlying NPAT growth for FY 2026.
Indue integration expected to deliver over 20% return on invested capital and $15–20m annual post-tax cost synergies by FY29.
Statutory EPS expected to be dilutive for the first two years post-acquisition due to integration timing.
First half earnings projected to represent about 55% of full-year underlying NPAT due to seasonally strong H1.
No material impact expected from surcharging or interchange changes in the near term.
Latest events from Cuscal
- Profit up 21% to $31.6m, dividend increased, and IPO targeted for late 2024.CCL
H2 202425 Mar 2026 - Pro forma NPAT up 42% to $21.5m, with 7% transaction volume growth and strong capital.CCL
H1 202511 Oct 2025 - FY25 results beat forecasts; Indue acquisition to deliver major cost synergies and EPS growth.CCL
H2 202511 Oct 2025 - Strong H1 FY25 growth and innovation position the business for further expansion.CCL
ASX SMIDcaps Conference Presentation8 Oct 2025